search
Back to results

Montelukast as Prophylaxis for Upper Respiratory Tract Infections in Children: a Randomised, Double-blind, Placebo-controlled Study

Primary Purpose

Upper Respiratory Tract Infection

Status
Unknown status
Phase
Phase 3
Locations
Israel
Study Type
Interventional
Intervention
Muntelukast
Placebo
Sponsored by
Assaf-Harofeh Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Upper Respiratory Tract Infection focused on measuring Montelukast, Upper respiratory tract infection, leukotriene, Children

Eligibility Criteria

1 Year - 5 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Children 1 to 5 years old without significant health problem.

Exclusion Criteria:

  • A previous history of wheezing (requiring treatment with bronchodilators in the last 3 month or more than one treatment in the last year)
  • Hospital admission due to reactive air way disease
  • Prophylactic use of montelukast or steroids
  • Chronic cardiac or respiratory disease
  • Presence of acute respiratory tract infection within the 7 days before consideration for the study
  • History of allergic Rhinitis
  • Children who are receiving chronic medications of any kind
  • Known allergy to montelukast
  • Inability to get an informed consent from a legal guardian.

Sites / Locations

  • Kupat Cholim ClalitRecruiting
  • Kupat Cholim ClalitRecruiting
  • Assaf HarofehRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

A

B

Arm Description

Outcomes

Primary Outcome Measures

The number and duration of URI episodes

Secondary Outcome Measures

Severity of URI episodes,number of days with fever,antibiotic and antipyretic usage, unscheduled visits to physicians office, child's absence from day care or kindergarten, parental absence from work, hospital admissions and adverse reaction of the drug.

Full Information

First Posted
October 30, 2007
Last Updated
March 16, 2010
Sponsor
Assaf-Harofeh Medical Center
Collaborators
Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00551382
Brief Title
Montelukast as Prophylaxis for Upper Respiratory Tract Infections in Children: a Randomised, Double-blind, Placebo-controlled Study
Official Title
Phase 3 Study of Montelukast as Prophylaxis for Upper Respiratory Tract Infections in Children
Study Type
Interventional

2. Study Status

Record Verification Date
March 2010
Overall Recruitment Status
Unknown status
Study Start Date
November 2007 (undefined)
Primary Completion Date
December 2009 (Anticipated)
Study Completion Date
June 2010 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Assaf-Harofeh Medical Center
Collaborators
Merck Sharp & Dohme LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Viral upper respiratory tract infection (URI) is one of the most common diseases among toddlers and pre-school children.Complete and effective prevention measures for URI are currently unavailable. Montelukast (Singulair ) is a selective leukotriene-receptor antagonist that inhibits the cysteinyl leukotriene 1 receptor. It is well tolerated and safe even in young children. Montelukast is an effective treatment for asthma (and allergic rhinitis from 1 year of age. Infections with viruses causing URI such as Influenza A, Rhinovirus and respiratory syncitial virus increases leukotriens levels in nasal secretions. Therefore, one may postulate that leukotriens inhibitors may reduce symptoms during URI. However the effect of montelukast as a treatment for non-specific cough was not properly studied and there are no studies on the effect of montelukast as prevention for URI. Hypothesis: Prophylactic treatment with Montelukast will reduce the incidence and severity of upper respiratory infection in children.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Upper Respiratory Tract Infection
Keywords
Montelukast, Upper respiratory tract infection, leukotriene, Children

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Experimental
Arm Title
B
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Muntelukast
Other Intervention Name(s)
Singulair
Intervention Description
Tablets or granules; 4 mg once a day for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Look alike tablets or granules 1 per day for 12 weeks
Primary Outcome Measure Information:
Title
The number and duration of URI episodes
Time Frame
3 month
Secondary Outcome Measure Information:
Title
Severity of URI episodes,number of days with fever,antibiotic and antipyretic usage, unscheduled visits to physicians office, child's absence from day care or kindergarten, parental absence from work, hospital admissions and adverse reaction of the drug.
Time Frame
3 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Children 1 to 5 years old without significant health problem. Exclusion Criteria: A previous history of wheezing (requiring treatment with bronchodilators in the last 3 month or more than one treatment in the last year) Hospital admission due to reactive air way disease Prophylactic use of montelukast or steroids Chronic cardiac or respiratory disease Presence of acute respiratory tract infection within the 7 days before consideration for the study History of allergic Rhinitis Children who are receiving chronic medications of any kind Known allergy to montelukast Inability to get an informed consent from a legal guardian.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mati Berkovitch, MD
Phone
972 8 9779152
Email
mberkovitch@asaf.health.gov.il
First Name & Middle Initial & Last Name or Official Title & Degree
Eran Kozer, MD
Phone
972 8 9778131
Email
erank@asaf.health.gov.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mati Berkovitch, MD
Organizational Affiliation
Assaf-Harofeh Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eran Kozer, MD
Organizational Affiliation
Assaf-Harofeh Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kupat Cholim Clalit
City
Lod
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Al Garushi
First Name & Middle Initial & Last Name & Degree
Al Garushi, MD
Facility Name
Kupat Cholim Clalit
City
Ramla
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zachi Lotem
Facility Name
Assaf Harofeh
City
Zerifin
ZIP/Postal Code
70300
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Berkovitch
Phone
97289779152
First Name & Middle Initial & Last Name & Degree
Mati Berkovitch, MD

12. IPD Sharing Statement

Learn more about this trial

Montelukast as Prophylaxis for Upper Respiratory Tract Infections in Children: a Randomised, Double-blind, Placebo-controlled Study

We'll reach out to this number within 24 hrs